Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Q2 2024 Earnings Presentation
10 slides from Tarsus Pharmaceuticals's earnings presentation, Aug 8, 2024
Slide 1: Second Quarter 2024 Financial Results Conference Call
Tarsus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call August 8, 2024
Slide 2: Today's Speakers
Today’s Speakers Bobak Azamian, Aziz Mottiwala Jeff Farrow M.D., Ph.D. Chief Commercial Chief Financial Officer Chief Executive Officer and Chief Strategy Officer and Chairman Officer 2 © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations about future events that we believe
Slide 4: XDEMVY: Creating One of the Largest Categories in Eye Care
XDEMVY: Creating One of the Largest Categories in Eye Care Durable, robust patient outcomes1 – Millions of patients actively seeking solutions Exceptional, high-value payer coverage – $40.8M in XDEMVY net product sales with a net price >$1,000 per bottle High speed of ECP adoption – ~11,000 ECPs sta
Slide 5: Demodex Blepharitis is a Potential $1B+ Opportunity
Demodex Blepharitis is a Potential $1B+ Opportunity GOAL 1.5M 1.2M 2.2M 2.3M >7M Patients with Demodex Proactively blepharitis (DB) Dry Eye Rx patients Cataract patients Contact lens seeking treatment with DB1,3,4,5 with DB1,3,6 patients with DB1,3,7 for DB or Already diagnosed complementary & seeki
Slide 6: XDEMVY: An Eye Care Launch Unlike Any Other
XDEMVY®: An Eye Care Launch Unlike Any Other $40.8 million in Q2 net product sales Driving strong demand • Delivered more than 37,000 bottles to patients • Accelerated ECP adoption: ~11,000 prescribing with >60% prescribing to multiple patients ~25 Million1,2 High-value proposition • Durable and rob
Slide 7: Targeted Sales Force Increasing ECP Adoption
Targeted Sales Force Increasing ECP Adoption U T I L I Z AT I O N A C R O S S S E G M E N T S Early Adopters Eager Treaters New to DB (Diagnosing and treating patients (Ready for an FDA-approved solution; (Beginning to diagnose, recognizing on Day 1) ramping TRx alongside patient successes) prevalen
Slide 8: Second Quarter 2024 Financial Results
Second Quarter 2024 Financial Results XDEMVY: On-track to potentially be one of the best launches in eye care XDEMVY Net Sales XDEMVY Bottles ($ in millions) Delivered to Patients (in thousands) $40.8 37 $24.7 26 $13.1 15 $1.7 1.7 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2023 Q4 2023 Q1 2024 Q2 2024 ECPs
Slide 9: Q&A
Q&A Bobak Azamian, Aziz Mottiwala Jeff Farrow Sesha Neervannan, M.D., Ph.D. Ph.D. Chief Commercial Chief Financial Officer Chief Executive Officer and Chief Strategy Chief Operating Officer Officer and Chairman Officer 9 © Tarsus Pharmaceuticals | For Investor Purposes Only
Slide 10: Closing Remarks and Q&A
Closing Remarks and Q&A Dp Tarsus
Tarsus Pharmaceuticals — Q2 2024 Earnings Presentation on 6ix